Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal.
Pavlovsky C, Vasconcelos Cordoba B, Sanchez MB, Moiraghi B, Varela A, Custidiano R, Fernandez I, Freitas MJ, Ventriglia MV, Bendek G, Mariano R, Mela Osorio MJ, Pavlovsky MA, de Labanca AG, Foncuberta C, Giere I, Vera M, Juni M, Mordoh J, Sanchez Avalos JC, Cueto G, Miranda S, Levy EM, Bianchini M.
Pavlovsky C, et al. Among authors: sanchez mb.
J Hematol Oncol. 2023 Apr 29;16(1):43. doi: 10.1186/s13045-023-01440-6.
J Hematol Oncol. 2023.
PMID: 37120577
Free PMC article.